CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation

Kashima, K; Kawauchi, H; Tanimura, H; Tachibana, Y; Chiba, T; Torizawa, T; Sakamoto, H

Kashima, K (corresponding author), Chugai Pharmaceut Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.

MOLECULAR CANCER THERAPEUTICS, 2020; 19 (11): 2288

Abstract

Osimertinib is the only EGFR-tyrosine kinase inhibitor (TKI) capable of overcoming EGFR- T790M-mutated NSCLC, but osimertinib-resistant EGFR triple mu......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索